Synlab International GmbH has sold Synlab Lietuva laboratory network to Affidea Lietuva

Affidea Lietuva, a healthcare group owned by the Dutch capital group Affidea Diagnostics, has been cleared by the Competition Council to acquire and assume control of the medical company Synlab Lietuva.

The Competition Council has determined that the proposed concentration will not result in the creation or enhancement of a dominant position, nor will it restrict competition in the relevant markets.

SYNLAB is one of Europe’s largest providers of laboratory services, with a presence in over 30+ countries and a proven experience in the field of medical diagnostics, a strong scientific and consultancy base, and technologies based on clinical trials. SYNLAB laboratories offer over 5000 high quality and wide range of laboratory testing services.

Synlab Lietuva offers a range of services, including medical laboratory testing, vaccination services, and medical consultations, serving 94,000 patients annually. The company operated one central laboratory, one regional laboratory, and nine blood collection points across Lithuania.

Affidea Lietuva offers consultations, sports medicine, and other health services in its health centres, with laboratory testing conducted on-site. Therefore, this acquisition represents a significant strategic development in Lithuania, enabling the company to expand and strengthen its range of treatment services.

COBALT, together with CMS, advised SYNLAB International GmbH on the sale of all shares in SYNLAB Lietuva. The COBALT team consisted of Managing Partner Dr Irmantas Norkus and Specialist Counsel Deimantė Pagirienė. The CMS team was led by Managing Partner Dr Christopher Lächler.